The content on this site is intended for healthcare professionals only
Prof McVie chairs a session where Caroline Dive, Dr Nicolson and Dr Blackhall discuss and answer questions about developing new models and current standards of care in small cell lung cancer (SCLC) at the Future Horizons in Lung Cancer meeting.
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial
Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Uncommon genetic aberrations NTRK, RET, NRG
